Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.

Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma

Recent Results Cancer Res.

Authors: Dadu R, Hu MN, Grubbs EG, Gagel RF

Abstract

Two independent events--the identification of activating mutations of the RET proto-oncogene, a receptor tyrosine kinase, in medullary thyroid carcinoma, and the recognition that small organic molecules could bind to and inhibit phosphorylation of signaling molecules, thereby inactivating the pathway-led to the recognition that kinase inhibitors could be used to treat medullary thyroid carcinoma (MTC). The introduction of these compounds into clinical practice has transformed the treatment of metastatic MTC and provided insight into the mechanisms by which RET causes C-cell transformation. This chapter will review the progress in this field over the past 7 years.

PMID: 26494392 [PubMed - indexed for MEDLINE]



http://ift.tt/29BAX13